Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Two-stage, and Open Label Study to Evaluate the Safety and Tolerability of Using NaviFUS System in Patients With Drug Resistant Epilepsy

NCT03860298 is registered in ClinicalTrials.gov with NaviFUS Corporation as lead sponsor.

NCT NCT03860298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03860298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Two-stage, and Open Label Study to Evaluate the Safety and Tolerability of Using NaviFUS System in Patients With Drug Resistant Epilepsy
Lead sponsor
NaviFUS Corporation
Phase
Not applicable
Overall status
Completed
Start date
June 17, 2019
Completion date
October 14, 2020
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug refractory epilepsy, drug resistant epilepsy, epilepsy, drug refractory, epilepsy, drug resistant, epilepsy, intractable, intractable epilepsy, medication resistant epilepsy, refractory epilepsy